GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Cash From Discontinued Investing Activities

InnoCare Pharma (HKSE:09969) Cash From Discontinued Investing Activities : HK$0.0 Mil (TTM As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma Cash From Discontinued Investing Activities?

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

InnoCare Pharma's cash from discontinued investing activities for the three months ended in Sep. 2023 was HK$0.0 Mil. It means InnoCare Pharma received HK$0.0 Mil from discontinued investing activities. InnoCare Pharma's cash from discontinued investing activities for the trailing twelve months (TTM) ended in Sep. 2023 was HK$0.0 Mil.

InnoCare Pharma Cash From Discontinued Investing Activities Historical Data

The historical data trend for InnoCare Pharma's Cash From Discontinued Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Cash From Discontinued Investing Activities Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash From Discontinued Investing Activities
Get a 7-Day Free Trial - - - - -

InnoCare Pharma Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Cash From Discontinued Investing Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

InnoCare Pharma Cash From Discontinued Investing Activities Calculation

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Cash From Discontinued Investing Activities for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCare Pharma Cash From Discontinued Investing Activities Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Cash From Discontinued Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (HKSE:09969) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Cash From Discontinued Investing Activities
Comparable Companies
HKSE:01541 HKSE:09966 HKSE:06660 HKSE:01952 HKSE:02162 HKSE:06826 HKSE:02315 HKSE:01530 HKSE:06955 HKSE:02105 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
33C:Germany 688428:China
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
Website
https://www.innocarepharma.com
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (HKSE:09969) Headlines

No Headlines